<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">METOCURINE IODIDE</span><br/>(met-oh-kyoo'reen)<br/><span class="topboxtradename">Metubine Iodide<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">skeletal muscle relaxant</span>; <span class="classification">nondepolarizing</span><br/><b>Prototype: </b>Tubocurarine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Semisynthetic nondepolarizing neuromuscular blocking agent. Pharmacologic effects almost identical to those of tubocurarine
         but is reportedly 23 times more potent. Has a slightly shorter duration of action, less histamine-releasing effect,
         and produces less ganglionic blockade.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Produces skeletal muscle relaxation or paralysis by competing with acetylcholine at cholinergic receptor sites on skeletal
         muscle endplates, and thus blocks nerve impulse transmission.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunct to anesthesia to induce skeletal muscle relaxation. Has been used to reduce intensity of skeletal muscle contractions
         in drug- or electrically induced convulsions and to facilitate endotracheal intubation.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to metocurine or to iodides; allergies, asthma; lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Myasthenia gravis; renal, hepatic, or pulmonary impairment; respiratory depression; electrolyte disturbances; pregnancy (category
         C).
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Adjunct to General Anesthesia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 0.10.3 mg/kg over 3060 sec with 0.51 mg q3090 min prn<br/><br/><span class="indicationtitle">Adjunct for Intubation</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 0.20.4 mg/kg over 3060 sec<br/><br/><span class="indicationtitle">Electroshock Therapy</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 1.755.5 mg/kg<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Give undiluted.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> Direct:</span> Give over 3060 sec.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<span class="classification">alkaline solutions</span>. <span class="incompattype">Y-site:</span>
<span class="classification">barbiturates</span>, <b>meperidine,</b>
<b>morphine.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Protect solution from prolonged exposure to heat and direct sunlight.</li>
<li>Store at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Slight dizziness, feeling of warmth, malignant hyperthermia, hypersensitivity reactions. <span class="typehead">CV:</span>
<span class="speceff-common">Hypotension,</span> circulatory collapse. <span class="typehead">GI:</span> Decreased GI motility. <span class="typehead">Musculoskeletal:</span> Profound and prolonged muscle weakness and flaccidity. <span class="typehead">Respiratory:</span> Respiratory depression, hypoxia, apnea, increased bronchial and salivary secretions, bronchospasm. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Carbamazepine,</b>
<b>phenytoin</b> can lengthen time to neuromuscular blockade; may potentiate the effects of <b>botulinum toxin.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span>  14 min. <span class="typehead">Peak:</span> 35 min. <span class="typehead">Duration:</span> 3590 min. <span class="typehead">Distribution:</span> Crosses placenta. <span class="typehead">Elimination:</span> Primarily excreted in urine, small amount in feces. <span class="typehead">Half-Life:</span> 3.6 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>
            							Note: Complete recovery from IV dose may require several hours.
            						
         </li>
<li>Use a peripheral nerve stimulator to monitor response.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>